Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: The BIOCRT study

Heart Rhythm

Volumn 11, Issue 12, 2014, Pages 2167-2175

  Truong, Quynh A ^a,b   Januzzi, James L ^b   Szymonifka, Jackie ^b   Thai, Wai Ee ^b   Wai, Bryan ^b   Lavender, Zachary ^b   Sharma, Umesh ^b   Sandoval, Ryan M ^b   Grunau, Zachary S ^b   Basnet, Sandeep ^b   Babatunde, Adefolakemi ^b   Ajijola, Olujimi A ^c   Min, James K ^a   Singh, Jagmeet P ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

Biomarker; Cardiac resynchronization therapy; Coronary sinus; Galectin 3; Soluble ST2

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; GALECTIN 3; PROTEIN; PROTEIN ST2; UNCLASSIFIED DRUG; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; ARTICLE; BLOOD SAMPLING; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CARDIOVASCULAR DISEASE; CORONARY SINUS; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART GRAFT; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; VENOUS BLOOD; BLOOD; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROCEDURES; PROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; VEIN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; BLOOD SPECIMEN COLLECTION; CARDIAC RESYNCHRONIZATION THERAPY; CORONARY SINUS; FEMALE; FOLLOW-UP STUDIES; GALECTIN 3; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; VEINS;

EID: 84919346442     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2014.07.007     Document Type: Article

References (35)

1. W. Rosamond, K. Flegal, and G. Friday Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 115 2007 e69 e171
2. J.L. Januzzi Jr, W.F. Peacock, and A.S. Maisel Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study J Am Coll Cardiol 50 2007 607 613
3. S.U. Rehman, T. Mueller, and J.L. Januzzi Jr Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure J Am Coll Cardiol 52 2008 1458 1465
4. R.R. van Kimmenade, J.L. Januzzi Jr, P.T. Ellinor, U.C. Sharma, J.A. Bakker, A.F. Low, A. Martinez, H.J. Crijns, C.A. MacRae, P.P. Menheere, and Y.M. Pinto Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure J Am Coll Cardiol 48 2006 1217 1224
5. W.T. Abraham, W.G. Fisher, and A.L. Smith Cardiac resynchronization in chronic heart failure N Engl J Med 346 2002 1845 1853
6. J.G. Cleland, J.C. Daubert, E. Erdmann, N. Freemantle, D. Gras, L. Kappenberger, and L. Tavazzi The effect of cardiac resynchronization on morbidity and mortality in heart failure N Engl J Med 352 2005 1539 1549
7. M.R. Bristow, L.A. Saxon, and J. Boehmer Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure N Engl J Med 350 2004 2140 2150
8. G. Gregoratos, J. Abrams, A.E. Epstein, R.A. Freedman, D.L. Hayes, M.A. Hlatky, R.E. Kerber, G.V. Naccarelli, M.H. Schoenfeld, M.J. Silka, and S.L. Winters ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines) J Am Coll Cardiol 40 2002 1703 1719
9. P.E. Vardas, A. Auricchio, and J.J. Blanc Guidelines for cardiac pacing and cardiac resynchronization therapy: the task force for cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association Eur Heart J 28 2007 2256 2295
10. J.J. Bax, T. Abraham, and S.S. Barold Cardiac resynchronization therapy, Part 1: issues before device implantation J Am Coll Cardiol 46 2005 2153 2167
11. J.J. Bax, T. Abraham, and S.S. Barold Cardiac resynchronization therapy, Part 2: issues during and after device implantation and unresolved questions J Am Coll Cardiol 46 2005 2168 2182
12. J.L. Januzzi Jr, S.U. Rehman, and A.A. Mohammed Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction J Am Coll Cardiol 58 2011 1881 1889
13. P.A. McCullough, A. Olobatoke, and T.E. Vanhecke Galectin-3: a novel blood test for the evaluation and management of patients with heart failure Rev Cardiovasc Med 12 2011 200 210
14. B. Ky, B. French, and K. McCloskey High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure Circ Heart Fail 4 2011 180 187
15. M. Packer Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure J Card Fail 7 2001 176 182
16. E. Braunwald Biomarkers in heart failure N Engl J Med 358 2008 2148 2159
17. Writing Committee Memebers C.W. Yancy, and M. Jessup 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 128 2013 e240 e319
18. E.O. Weinberg, M. Shimpo, S. Hurwitz, S. Tominaga, J.L. Rouleau, and R.T. Lee Identification of serum soluble ST2 receptor as a novel heart failure biomarker Circulation 107 2003 721 726
19. M. Shimpo, D.A. Morrow, E.O. Weinberg, M.S. Sabatine, S.A. Murphy, E.M. Antman, and R.T. Lee Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction Circulation 109 2004 2186 2190
20. U.C. Sharma, S. Pokharel, T.J. van Brakel, J.H. van Berlo, J.P. Cleutjens, B. Schroen, S. Andre, H.J. Crijns, H.J. Gabius, J. Maessen, and Y.M. Pinto Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation 110 2004 3121 3128
21. R.A. de Boer, D.J. Lok, T. Jaarsma, P. van der Meer, A.A. Voors, H.L. Hillege, and D.J. van Veldhuisen Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction Ann Med 43 2011 60 68
22. R.V. Shah, A.A. Chen-Tournoux, M.H. Picard, R.R. van Kimmenade, and J.L. Januzzi Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure Eur J Heart Fail 12 2010 826 832
23. E.O. Weinberg, M. Shimpo, G.W. De Keulenaer, C. MacGillivray, S. Tominaga, S.D. Solomon, J.L. Rouleau, and R.T. Lee Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction Circulation 106 2002 2961 2966
24. D.A. Pascual-Figal, J. Ordonez-Llanos, P.L. Tornel, R. Vazquez, T. Puig, M. Valdes, J. Cinca, A.B. de Luna, and A. Bayes-Genis Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction J Am Coll Cardiol 54 2009 2174 2179
25. D.A. Pascual-Figal, S. Manzano-Fernandez, M. Boronat, T. Casas, I.P. Garrido, J.C. Bonaque, F. Pastor-Perez, M. Valdes, and J.L. Januzzi Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure Eur J Heart Fail 13 2011 718 725
26. A. Glick, Y. Michowitz, G. Keren, and J. George Neurohormonal and inflammatory markers as predictors of short-term outcome in patients with heart failure and cardiac resynchronization therapy Isr Med Assoc J 8 2006 391 395
27. R. Berger, A. Shankar, F. Fruhwald, A. Fahrleitner-Pammer, N. Freemantle, L. Tavazzi, J.G. Cleland, and R. Pacher Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study Eur Heart J 30 2009 2109 2116
28. A. Brenyo, A. Barsheshet, M. Rao, D.T. Huang, W. Zareba, S. McNitt, W.J. Hall, D.R. Peterson, S.D. Solomon, A.J. Moss, and I. Goldenberg Brain natriuretic peptide and cardiac resynchronization therapy in patients with mildly symptomatic heart failure Circ Heart Fail 6 2013 998 1004
29. N. Lopez-Andres, P. Rossignol, W. Iraqi, R. Fay, J. Nuee, S. Ghio, J.G. Cleland, F. Zannad, and P. Lacolley Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial Eur J Heart Fail 14 2012 74 81
30. R.K. Altman, K.A. Parks, and C.L. Schlett Multidisciplinary care of patients receiving cardiac resynchronization therapy is associated with improved clinical outcomes Eur Heart J 33 2012 2181 2188
31. B. Jorgensen, T. Bertsch, and H.J. Broker Multicentre evaluation of a second generation point-of-care assay with an extended range for the determination of N-terminal pro-brain natriuretic peptide Clin Lab 58 2012 515 525
32. T. Lepoutre, M.F. Rousseau, S.A. Ahn, and D. Gruson Measurement Nt-proBNP circulating concentrations in heart failure patients with a new point-of-care assay Clin Lab 59 2013 831 835
33. C.G. Jungbauer, B. Kaess, S. Buchner, C. Birner, M. Lubnow, M. Resch, K. Debl, M. Buesing, R. Zerback, G. Riegger, and A. Luchner Equal performance of novel N-terminal proBNP (Cardiac proBNP(R)) and established BNP (Triage BNP(R)) point-of-care tests Biomark Med 6 2012 789 796
34. http://investor.bg-medicine.com/releasedetail.cfm?ReleaseID=535701. Accessed December 31, 2013.
35. http://www.criticaldiagnostics.com/US/news/news-101513.html. Accessed December 31, 2013.